The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending conditional approval of Roche’s (OTCQX:RHHBY) Polivy (polatuzumab vedotin), an antibody-drug conjugate, for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in combination with Rituxan (rituximab) and chemo agent bendamustine.
A final decision from the European Commission usually takes ~60 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.